Search

Your search keyword '"Descamps E"' showing total 91 results
Start Over Author "Descamps E"
91 results on '"Descamps E"'

3. Link between postoperative ileus and anastomotic leakage: A structural equation modelling approach

Author

Abderrazak, M., Abolo, H., Abras, N., Aissou, M., Albertini, S., Alfonsi, P., Andre, A., Arimont, J.M., Arnalsteen, L., Atger, J., Attias, A., Aumont, O., Auvray, S., Bachmann, R., Barabino, G., Barsotti, P., Beauchesne, B., Beaupel, N., Beliard, A., Bellouard, A., Beloeil, H., Ben Salem, F., Benhamou, A., Billard, V., Binhas, M., Binot, D., Blache, J.L., Blet, A., Bongiovanni, J.P., Bonnal, A., Bonnet, M., Boret, H., Bossard, A.E., Bothereau, H., Bouarroudj, N., Bouayed, A., Bouchard, F., Boumadani, M., Bousquet, M., Bouygues, V., Bozio, G., Brek, A., Cadi, P., Caillon, P., Camerlo, A., Capito, C., Cardin, J.L., Castiglioni, M., Catinois, M.L., Cattan, P., Chambrier, C., Chambrier, G., Chapuis, O., Chauvin, M., Chokairi, S., Chopin Laly, X., Collange, V., Cotte, E., Cuellar, E., D'errico, E., Dahmani, S., Danan, M., De La Fontaine, C., De Wailly, P., Degauque, C., Delacoste, F., Denet, C., Denost, Q., Desaint, P., Descamps, E., Desfourneaux., V, Desmet, J., Desolneux, G., Dileon, S., Dolbeau, J.B., Douard, R., Dufour, F., Dupont-Bierre, E., Dupré, A., Entremont, A., Faucheron, J.L., Fernoux, P., Figuet, S., Finianos, A., Flamein, R., Fletcher, D., Fontes, J.P., Fourn, E., Gergeanu, S., Germain, A., Gignoux, B., Goater, P., Gres., P, Grigoroiu, M., Grillo, P., Guignard, B., Guinier, D., Guiot, J.L., Gutton, C., Hadjadj, H., Hail, K., Hausermann, M.H., Hennequin, S., Homsy-Hubert, B., Jambet, S., Janecki, T., Jannier-Guillou, V., Jaspart, J., Joly, F., Joris, J., Journe, F., Kattou, F., Kemoun, G., Khalaf, M., Klack, F., Kothonidis, K., Kurdi, O., Laforest, A., Lamblin, A., Lammens, S., Laporte, S., Launay-Savary, M.V., Le Maho, A.L., Lemée, J.M., Leonard, D., Leporrier, J., Lorin, J.L., Magne, E., Maisonnette, F., Malherbe, V., Manceau, G., Mariani, P., Massalou, D., Massard, J.L., Mauvais, F., Mbuyamba, J., Mbuyamba Katapile, J., Mehila, T., Meillat, H., Mergui, C., Michaud, P., Milou, F., Mirre, F., Mor Martinez, C., Mouchon, S., Mouilhade, F., Nguyen, Y.L., Ostermann Bucher, S., Page, M., Parent, S., Payen, A.L., Pedicone, R., Peluchon, P., Pichot-Delahaye, V., Piquard, A., Pirlet, I., Plard, L., Poiblanc, M., Poinas, G., Poincenot, J., Ponchel, C., Pontallier, A., Pop, R., Potiron, E., Proske, J.M., Prunet, B., Ras, E., Raspado, O., Raux, M., Regimbeau, J.M., Remue, C., Renacco, F., Riboud, R., Richard-Payen, A.L., Rio, D., Sage, M., Sage, P.Y., Saint Denis, M., Salaun, P., Samyn, B., Sbai Idrissi, M., Schmitt, G., Secq, E., Seddiki, A., Sens, N., Sirieix, D., Siriser, F., Tarcea, M., Tavernier, M., Tete, B., Theissen-Laval, O., Thevenot, A., Thievenaz, R., Vacher, B., Verhaeghe, R., Verrier, J.F., Vieuille, C., Voilin, C., Vuagnat, C., Zaepfel, S., Venara, Aurélien, Hamel, Jean-Francois, Beyer-Berjot, Laura, Vignaud, Timothée, and Slim, Karem

Published
2021
Full Text
View/download PDF

12. Link between postoperative ileus and anastomotic leakage: A structural equation modelling approach

Author

Venara, Aurélien, primary, Hamel, Jean-Francois, additional, Beyer-Berjot, Laura, additional, Vignaud, Timothée, additional, Slim, Karem, additional, Abderrazak, M., additional, Abolo, H., additional, Abras, N., additional, Aissou, M., additional, Albertini, S., additional, Alfonsi, P., additional, Andre, A., additional, Arimont, J.M., additional, Arnalsteen, L., additional, Atger, J., additional, Attias, A., additional, Aumont, O., additional, Auvray, S., additional, Bachmann, R., additional, Barabino, G., additional, Barsotti, P., additional, Beauchesne, B., additional, Beaupel, N., additional, Beliard, A., additional, Bellouard, A., additional, Beloeil, H., additional, Ben Salem, F., additional, Benhamou, A., additional, Billard, V., additional, Binhas, M., additional, Binot, D., additional, Blache, J.L., additional, Blet, A., additional, Bongiovanni, J.P., additional, Bonnal, A., additional, Bonnet, M., additional, Boret, H., additional, Bossard, A.E., additional, Bothereau, H., additional, Bouarroudj, N., additional, Bouayed, A., additional, Bouchard, F., additional, Boumadani, M., additional, Bousquet, M., additional, Bouygues, V., additional, Bozio, G., additional, Brek, A., additional, Cadi, P., additional, Caillon, P., additional, Camerlo, A., additional, Capito, C., additional, Cardin, J.L., additional, Castiglioni, M., additional, Catinois, M.L., additional, Cattan, P., additional, Chambrier, C., additional, Chambrier, G., additional, Chapuis, O., additional, Chauvin, M., additional, Chokairi, S., additional, Chopin Laly, X., additional, Collange, V., additional, Cotte, E., additional, Cuellar, E., additional, D'errico, E., additional, Dahmani, S., additional, Danan, M., additional, De La Fontaine, C., additional, De Wailly, P., additional, Degauque, C., additional, Delacoste, F., additional, Denet, C., additional, Denost, Q., additional, Desaint, P., additional, Descamps, E., additional, Desfourneaux., V, additional, Desmet, J., additional, Desolneux, G., additional, Dileon, S., additional, Dolbeau, J.B., additional, Douard, R., additional, Dufour, F., additional, Dupont-Bierre, E., additional, Dupré, A., additional, Entremont, A., additional, Faucheron, J.L., additional, Fernoux, P., additional, Figuet, S., additional, Finianos, A., additional, Flamein, R., additional, Fletcher, D., additional, Fontes, J.P., additional, Fourn, E., additional, Gergeanu, S., additional, Germain, A., additional, Gignoux, B., additional, Goater, P., additional, Gres., P, additional, Grigoroiu, M., additional, Grillo, P., additional, Guignard, B., additional, Guinier, D., additional, Guiot, J.L., additional, Gutton, C., additional, Hadjadj, H., additional, Hail, K., additional, Hausermann, M.H., additional, Hennequin, S., additional, Homsy-Hubert, B., additional, Jambet, S., additional, Janecki, T., additional, Jannier-Guillou, V., additional, Jaspart, J., additional, Joly, F., additional, Joris, J., additional, Journe, F., additional, Kattou, F., additional, Kemoun, G., additional, Khalaf, M., additional, Klack, F., additional, Kothonidis, K., additional, Kurdi, O., additional, Laforest, A., additional, Lamblin, A., additional, Lammens, S., additional, Laporte, S., additional, Launay-Savary, M.V., additional, Le Maho, A.L., additional, Lemée, J.M., additional, Leonard, D., additional, Leporrier, J., additional, Lorin, J.L., additional, Magne, E., additional, Maisonnette, F., additional, Malherbe, V., additional, Manceau, G., additional, Mariani, P., additional, Massalou, D., additional, Massard, J.L., additional, Mauvais, F., additional, Mbuyamba, J., additional, Mbuyamba Katapile, J., additional, Mehila, T., additional, Meillat, H., additional, Mergui, C., additional, Michaud, P., additional, Milou, F., additional, Mirre, F., additional, Mor Martinez, C., additional, Mouchon, S., additional, Mouilhade, F., additional, Nguyen, Y.L., additional, Ostermann Bucher, S., additional, Page, M., additional, Parent, S., additional, Payen, A.L., additional, Pedicone, R., additional, Peluchon, P., additional, Pichot-Delahaye, V., additional, Piquard, A., additional, Pirlet, I., additional, Plard, L., additional, Poiblanc, M., additional, Poinas, G., additional, Poincenot, J., additional, Ponchel, C., additional, Pontallier, A., additional, Pop, R., additional, Potiron, E., additional, Proske, J.M., additional, Prunet, B., additional, Ras, E., additional, Raspado, O., additional, Raux, M., additional, Regimbeau, J.M., additional, Remue, C., additional, Renacco, F., additional, Riboud, R., additional, Richard-Payen, A.L., additional, Rio, D., additional, Sage, M., additional, Sage, P.Y., additional, Saint Denis, M., additional, Salaun, P., additional, Samyn, B., additional, Sbai Idrissi, M., additional, Schmitt, G., additional, Secq, E., additional, Seddiki, A., additional, Sens, N., additional, Sirieix, D., additional, Siriser, F., additional, Tarcea, M., additional, Tavernier, M., additional, Tete, B., additional, Theissen-Laval, O., additional, Thevenot, A., additional, Thievenaz, R., additional, Vacher, B., additional, Verhaeghe, R., additional, Verrier, J.F., additional, Vieuille, C., additional, Voilin, C., additional, Vuagnat, C., additional, and Zaepfel, S., additional

Published
2021
Full Text
View/download PDF

15. Étude prospective de séroprévalence du Sars-Cov-2 chez 249 patients suivis pour un rhumatisme inflammatoire chronique

Author

Fogel, O., primary, Mariaggi, A.A., additional, Méritet, J.F., additional, André, E., additional, Boisson, M., additional, Combier, A., additional, Descamps, E., additional, Frantz, C., additional, Wanono, S., additional, Morel, J., additional, Avouac, J., additional, Rozenberg, F., additional, and Miceli Richard, C., additional

Published
2020
Full Text
View/download PDF

16. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

Author

Raymond, E, Nicot, F., Morand-Joubert, A, Rodallec, D, Mourez, M, Beby-Defaux, D, Lambert-Niclot, P, Charpentier, E, Malvé, B., Le Guillou-Guillemette, A, Si-Mohamed, D, Avettand Fenoel, A, Roussel, A., Calvez, P, Saune, E, Rodriguez, M, Descamps, E, Izopet, E, Lagier, E, Roussel, C, Le Guillou-Guillemette, G, Alloui, A., Bettinger, D., Pallier, P, Fleury, Frédéric, Reigadas, R, Bellecave, P., Recordon-Pinson, P, Payan, P, Vallet, S., Vabret, A., Dina, D, Henquell, C., Mirand, A., Bouvier-Alias, A, de Rougemont, A, Dos Santos, D, Morand, P, Signori-Schmuck, A., Bocket, B, Rogez, R, Andre, A, Tardy, C, Trabaud, A, Tamalet, C., Delamare, D, Montes, B, SCHVOERER, Evelyne, Ferré, F., André-Garnier, E., Cottalorda, C, Guinard, G, Guiguon, A, Descamps, D., Brun-Vézinet, B, Charpentier, c, Visseaux, B, Peytavin, G., Krivine, A., Si-Mohamed, A, Avettand-Fenoel, Véronique, Marcelin, A, Calvez, C, Lambert-Niclot, L, Soulié, C., Wirden, M., Morand-Joubert, M, Delaugerre, D, Chaix, M, Amiel, A, Schneider, S., Giraudeau, G, Beby- Defaux, D, Brodard, B, Maillard, A., Plantier, P, Chaplain, C, Bourlet, B, Fafi-Kremer, F, Stoll-Keller, F., Schmit, P, Barth, B, Yerly, S, Poggi, P., Izopet, I, Raymond, R, Barin, B, Chaillon, A, Marque-Juillet, M, Roque-Afonso, A, Haïm-Boukobza, B, Flandre, P., Grudé, G, Assoumou, A, Costagliola, D, Allegre, A, Schmit, J, Chennebault, M, Bouchaud, B, Magy-Bertrand, B, Delfraissy, D, Dupon, D, Morlat, P, Neau, D, Ansart, A., Jaffuel, J, Verdon, R, Jacomet, C, Lévy, L, Dominguez, D, Chavanet, P., Piroth, P, Cabié, A., Leclercq, P, Ajana, A, Cheret, A, Weinbreck, P, Cotte, C, Poizot-Martin, P, Ravaud, R., Christian, B, Truchetet, F, Grandidier, G, Rey, R., May, M, Goehringer, G, Raffi, F., Dellamonica, D, Prazuck, P, Hocqueloux, L, Landman, R, Yazdanpanah, Y., Launay, L, WEISS, L, Viard, P, Katlama, C., Simon, A., Girard, G, Meynard, M, Molina, M, Pialoux, G, Hoen, B., Goeger-Sow, G, Lamaury, I, Beaucaire, G, Le Moal, G., Jaussaud, R., Rouger, C, Michelet, M., Borsa-Lebas, B, Caron, F, Khuong, A., Lucht, F., Rey, D., Calmy, A, Lafeuillade, A, Marchou, B, Delobel, D, Gras, G, Greder-Belan, A, Vittecoq, D, Teiche, E, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées, Laboratoire de virologie [CHU Toulouse], CHU Toulouse [Toulouse], Hôpital Paul Brousse, CHU Bordeaux [Bordeaux], Laboratoire de Virologie [Rennes] = Virology [Rennes], CHU Pontchaillou [Rennes], Hospices Civils de Lyon (HCL), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universiatire Hôtel-Dieu de Nantes (CHU Hôtel-Dieu), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Rouen, Centre Hospitalier Universitaire de Lille (CHU de Lille), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hôpital Henri Mondor, CHU Pitié-Salpêtrière [AP-HP], Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), INSERM UMR-S 606, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, PRES Sorbonne Paris-Cité, and Université Paris Denis Diderot, Université Paris Diderot - Paris 7 (UPD7), Laboratoire de Virologie [AP-HP Hôpital Bichat-Claude-Bernard], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Nancy (CHU Nancy), CHU Clermont-Ferrand, Service de Virologie [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses [CH Versailles] (CeRéMAIA - Hôpital André Mignot), Centre Hospitalier de Versailles André Mignot (CHV), Centre hospitalier universitaire de Grenoble (CHU de Grenoble), CHU Grenoble, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital Necker, Centre Hospitalier Universitaire d'Amiens, Institut National de la Santé et de la Recherche Médicale (INSERM), AP-HP, Hôpital Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique et Maladies Infectieuses 94000 Créteil, France, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Agence Nationale de Recherches sur le SIDA et les hepatites virales (French National Agency for Research on AIDS and Viral Hepatitis, ANRS), Janssen-Cilag SAS, Erosion torrentielle neige et avalanches (UR ETGR (ETNA)), Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Service de Virologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Laboratoire de Pharmacologie Médicale, Institut National de la Santé et de la Recherche Médicale (INSERM)-Faculté de Médecine/CHU, CHU Besançon, Université de Franche-Comté (UFC), Génétique et évolution des interactions hôtes-parasites, Département génétique, interactions et évolution des génomes [LBBE] (GINSENG), Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Laboratoire Universitaire de Biodiversité et Ecologie Microbienne (LUBEM), Université de Brest (UBO), Laboratoire de Virologie Humaine et Moléculaire [Caen], Laboratoire de biologie structurale des interactions entre virus et cellule hôte, Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Chimie Physique et Microbiologie pour les Matériaux et l'Environnement (LCPME), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Génomique et épigénétique des pathologies placentaires (Inserm U709), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôtel-Dieu de Nantes, Centre d'Etudes Lasers Intenses et Applications (CELIA), Université de Bordeaux (UB)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], CHU Necker - Enfants Malades [AP-HP], Laboratoire de Virologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Service de Virologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), AgroParisTech, T1, Laboratoire Matériaux Optiques, Photonique et Systèmes (LMOPS), CentraleSupélec-Université de Lorraine (UL)-CentraleSupélec-Université de Lorraine (UL), Interaction virus-hôte et maladies du foie, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sciences pour l'environnement (SPE), Université Pascal Paoli (UPP)-Centre National de la Recherche Scientifique (CNRS), Département d'infectiologie (CHU de Dijon), Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Laboratoire d'Acoustique de l'Université du Mans (LAUM), Centre National de la Recherche Scientifique (CNRS)-Le Mans Université (UM), ONERA - The French Aerospace Lab [Toulouse], ONERA, Service des maladies infectieuses et tropicales [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), UMR CNRS 8179, Centre National de la Recherche Scientifique (CNRS)-Université de Lille, Sciences et Technologies, Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de Médecine Interne, Maladies Infectieuses et Tropicales (POTIERS - Mal Inf), Service de Médecine interne, Maladies Infectieuses et Immunologie Clinique [Reims], Centre Hospitalier Universitaire de Reims (CHU Reims), Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherches sur la Cognition Animale (CRCA), Institut des sciences du cerveau de Toulouse. (ISCT), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), University Hospital and University Jean Monnet, Laboratoire d'Ecologie Alpine (LECA), Centre National de la Recherche Scientifique (CNRS)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Université Joseph Fourier - Grenoble 1 (UJF)-Université Grenoble Alpes (UGA), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Biologie structurale des interactions entre virus et cellule hôte (UVHCI), Université Joseph Fourier - Grenoble 1 (UJF)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Bordeaux (UB), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université, Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP), CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Institut National de la Santé et de la Recherche Médicale (INSERM)-Université des Antilles et de la Guyane (UAG), Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), Laboratoire Chrono-environnement - CNRS - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Service de Médecine Interne, Maladies Infectieuses et Tropicales [CHU Poitiers], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut des sciences du cerveau de Toulouse. (ISCT), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre de Biologie Intégrative (CBI), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Ecologie Alpine (LECA ), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Hôpital de la Pitié-Salpêtrière, Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC)

Subjects
0301 basic medicine, Male, Drug Resistance, HIV Infections, Drug resistance, Medical and Health Sciences, chemistry.chemical_compound, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, 2.1 Biological and endogenous factors, Viral, Aetiology, Articles and Commentaries, ComputingMilieux_MISCELLANEOUS, minority resistant variants, Viral Load, Biological Sciences, first-line antiretroviral therapy, 3. Good health, Infectious Diseases, Rilpivirine, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, HIV/AIDS, Female, Infection, Viral hepatitis, Viral load, Microbiology (medical), Adult, ultra-deep sequencing, Microbiology, Virus, rilpivirine, 03 medical and health sciences, Acquired immunodeficiency syndrome (AIDS), Clinical Research, Drug Resistance, Viral, Genetics, medicine, Humans, business.industry, Genetic Variation, medicine.disease, Virology, Reverse transcriptase, Regimen, Good Health and Well Being, 030104 developmental biology, chemistry, Mutation, HIV-1, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group, Antimicrobial Resistance, business
Abstract

Background Minority resistant variants of human immunodeficiency virus type 1 (HIV-1) could influence the virological response to treatment based on nonnucleoside reverse transcriptase inhibitors (NNRTIs). Data on minority rilpivirine-resistant variants are scarce. This study used next-generation sequencing (NGS) to identify patients harboring minority resistant variants to nucleos(t)ide reverse transcriptase inhibitors and NNRTIs and to assess their influence on the virological response (VR). Methods All the subjects, 541 HIV-1–infected patients started a first-line regimen containing rilpivirine. VR was defined as a HIV-1 RNA load Results NGS revealed resistance-associated mutations accounting for 1% to 20% in 29% of samples. We identified 43 (8.8%) and 36 (7.4%) patients who harbored rilpivirine-resistant variants with a 1% sensitivity threshold according to the French National Agency for Research on AIDS and Viral Hepatitis and Stanford algorithms, respectively. The VR was 96.9% at month 12. Detection of minority rilpivirine resistant variants was not associated with virological failure (VF). Multivariate analysis indicated that VF at month 12 was associated with a CD4 count Conclusions Minority resistant variants had no impact on the VR of treatment-naive patients to a rilpivirine-based regimen.

Published
2018
Full Text
View/download PDF

23. Approaching maximal precision of Hong-Ou-Mandel interferometry with non-perfect visibility

Author

Meskine Othmane, Descamps Eloi, Keller Arne, Lemaître Aristide, Baboux Florent, Ducci Sara, and Milman Pérola

Subjects
Physics, QC1-999
Abstract

This work explores precision limits in two-photon Hong-Ou-Mandel interferometry under non-perfect visibility. A theoretical model is developed and experimentally validated using different quantum states. A remarkable ratio of 0.97 between the experimental precision and the quantum limit is observed, establishing a new benchmark in the field.

Published
2024
Full Text
View/download PDF

24. Cloning the Mycoplasma hominis PG21 Genome in Saccharomyces cerevisiae as a Yeast Centromeric Plasmid

Author

Descamps, E., Le Roy, Chloé, Renaudin, Hélène, Lartigue, Carole, Bebear, Cecile, Université Sciences et Technologies - Bordeaux 1, CHU Bordeaux [Bordeaux], Biologie du fruit et pathologie (BFP), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA)-Université Sciences et Technologies - Bordeaux 1, and ProdInra, Migration

Subjects
[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, [SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience

Published
2014

27. Lustrumboek 2006-2007-2008-2009-2010

Author

Bervoets, R., Cypers, K., Moortgat, T., Vuylsteke, T., Vanhessche, U., Descamps, E., Bertens, R., De Canck, S., Vandevelde, Y., Devriendt, C., and Pauwels, J.

Subjects
Harbours
Published
2011

32. Jaarboek 2009

Author

Bervoets, R., Cypers, K., Moortgat, T., Vuylsteke, T., Vanhessche, U., Descamps, E., Bertens, R., De Canck, S., Vandevelde, Y., Devriendt, C., and Pauwels, J.

Published
2010

33. Jaarboek 2007

Author

Vuylsteke, T., Bervoets, R., Pauwels, J., Descamps, E., Bertens, R., Vandevelde, Y., Moortgat, T., Vanhessche, U., De Canck, S., and Cypers, K.

Published
2008

34. New Maritime Rescue Coordination Centre (MRCC) for Ostend

Author

Descamps, E.

Subjects
Navigation regulations, Harbours, ANE, Belgium, Oostende Harbour
Abstract

the Shipping Assistance Division of the Flemish Government. The MRCC Ostend is offering a state-of-the-art and integrated platform for Vessel Traffic Monitoring, Incident Management and Search and Rescue functionalities to ensure safety and to coordinate rescue actions at sea. This article provides a practical insight into the advanced Traffic Monitoring functionalities and technologies of the MRCC. It also shows how the MRCC system will be ready to cope with the challenges of the future. The MRCC in Ostend is the central check point for incidents at sea, including persons and vessels in need, accidents and oil pollution. In view of the ever increasing traffic on the North Sea and the increasingly strict European and international regulations, the Flemish Government saw the need for a modern and sophisticated MRCC. The new centre in Ostend, equipped with the latest monitoring and communication technology, will play a very important role in maintaining the safety and environmental friendliness of our coastal waters and in providing the best possible response and accommodation in case of an incident. The MRCC needs to cooperate with several international, federal, regional and local authorities and organisations. The centre is therefore linked to several (external and internal) databases and is equipped with an Incident Management System for the follow up, coordination and reporting of calamities. The actual traffic image at sea and all other relevant information is available for all partners within the coast guard organisation. External communication is an important aspect of the MRCC’s responsibility, e.g. for notifying the press in case of any calamities. To that purpose, both a control room and a meeting room have been equipped with all necessary communication tools in order to be able to follow up, control or report on possible rescue operations. Along with its role as maritime coordination centre, the new MRCC’s meeting room will also be used as incident room and press information centre.

Published
2006

39. Copper electrodeposition localized in picoliter droplets using microcantilever arrays.

Author

Leïc;hlé, T., Nicu, L., Descamps, E., Corso, B., Mailley, P., Livache, T., and Bergaud, C.

Subjects
COPPER, ELECTROFORMING, ELECTROCHEMISTRY, ELECTROMETALLURGY, METALS
Abstract

A patterning tool that allows electrochemical reactions to take place inside microdroplets is introduced. This tool relies on the use of a microfabricated array of silicon cantilevers that incorporate a channel into which a gold electrode is patterned. The deposition process consists in forming picoliter droplets onto a conducting surface by a contact method and applying a voltage between the surface and the cantilevers. To demonstrate the capability of the system, arrays of 20 μm diameter copper islands are electrodeposited onto gold surfaces. As expected, the copper bumps exhibit increasing heights as a result of longer deposition times. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

42. Changes of cerebral functional connectivity induced by foot reflexology in a RCT.

Author

Descamps E, Boussac M, Joineau K, and Payoux P

Subjects
Humans, Foot, Pain, Head, Magnetic Resonance Imaging methods, Brain, Brain Mapping methods
Abstract

Non-Pharmacological Interventions (NPIs) are increasingly being introduced into healthcare, but their mechanisms are unclear. In this study, 30 healthy participants received foot reflexology (FR) and sham massage, and went through a resting-state functional magnetic resonance imaging (rs-fMRI) to evaluate NPIs effect on brain. Rs-fMRI revealed an effect of both NPIs on functional connectivity with changes occurring in the default-mode network, the sensorimotor network and a Neural Network Correlates of Pain (NNCP-a newly discovered network showing great robustness). Even if no differences were found between FR and SM, this study allowed to report brain biomarkers of well-being as well as the safety of NPIs. In further research, it could be relevant to study it in patients to look for a true reflexology induced-effect dependent of patient reported outcomes. Overall, these findings enrich the understanding of the neural correlates of well-being experienced with NPIs and provided insight into the basis of the mechanisms of NPIs., (© 2023. Springer Nature Limited.)

Published
2023
Full Text
View/download PDF

43. Quantum Metrology Using Time-Frequency as Quantum Continuous Variables: Resources, Sub-Shot-Noise Precision and Phase Space Representation.

Author

Descamps E, Fabre N, Keller A, and Milman P

Abstract

We study the role of the electromagnetic field's frequency on the precision limits of time measurements from a quantum perspective, using single photons as a paradigmatic system. We demonstrate that a quantum enhancement of precision is possible only when combining both intensity and spectral resources and, in particular, that spectral correlations enable a quadratic scaling of precision with the number of probes. We identify the general mathematical structure of nonphysical states that achieve the Heisenberg limit and show how a finite spectral variance may cause a quantum-to-classical-like transition in precision scaling for pure states similar to the one observed for noisy systems. Finally, we provide a clear and consistent geometrical time-frequency phase space interpretation of our results, identifying what should be considered as spectral classical resources.

Published
2023
Full Text
View/download PDF

44. Whipple's disease: a rare cause of sacroiliitis.

Author

Bouchut A, Al Tabaa O, Descamps E, Puechal X, and Roux C

Subjects
Humans, Whipple Disease complications, Whipple Disease diagnosis, Whipple Disease drug therapy, Sacroiliitis diagnosis, Sacroiliitis etiology, Arthritis diagnosis, Arthritis etiology
Abstract

Competing Interests: Competing interests: None declared.

Published
2022
Full Text
View/download PDF

45. Evaluation of Patients With Rheumatoid Arthritis in Teleconsultation During the First Wave of the COVID-19 Pandemic.

Author

Avouac J, Molto A, Frantz C, Wanono S, Descamps E, Fogel O, Combier A, Poiroux L, Miceli-Richard C, and Allanore Y

Subjects
Female, Humans, Middle Aged, Pandemics, Cross-Sectional Studies, Retrospective Studies, Remote Consultation, COVID-19, Arthritis, Rheumatoid drug therapy
Abstract

Objective: To describe which variables were collected by rheumatologists to monitor patients with rheumatoid arthritis (RA) during teleconsultation and identify which ones have more impact on clinician intervention., Methods: Retrospective monocentric, routine care cross-sectional study including patients with RA seen in teleconsultation between March and September 2020. Available variables assessing disease status were collected in teleconsultation files. Clinician intervention was defined by treatment escalation and/or the need for a rapid face-to-face consultation or day hospitalization., Results: One hundred forty-three patients with RA were included (116 females, mean age of 58 [SD 16] yrs, mean disease duration of 14 [SD 11] yrs). The presence or absence of patient self-reported RA flares was mentioned in all medical files, followed by the presence and/or the number of tender joints (76%), the duration of morning stiffness (66%), the number of pain-related nocturnal awakenings (66%) and the C-reactive protein (CRP) value (54%). Teleconsultation led to a clinician intervention in 22/143 patients (15%), representing 51% of patients with self-reported flares (22/43 patients). Therapeutic escalation was necessary in 13 patients and/or face-to-face consultation or day hospitalization were organized for 10 patients. Multivariate analysis identified RA flares (odds ratio [OR] 15.6, 95% CI 3.37-68.28) and CRP values > 10 mg/L (OR 3.32, 95% CI % 1.12-13.27) as the variables independently associated with clinician intervention., Conclusion: Our study identified patient-reported RA flares and increased CRP values as 2 red flags in teleconsultation, independently associated with therapeutic modification and/or the need for a rapid face-to-face consultation. These indicators may help clinicians' decision making in teleconsultation., (Copyright © 2022 by the Journal of Rheumatology.)

Published
2022
Full Text
View/download PDF

47. Systematic assessment of the humoral response against SARS-CoV-2 in a French cohort of 283 patients with rheumatic diseases.

Author

Gros C, Mariaggi AA, Meritet JF, André E, Boisson M, Combier A, Descamps E, Frantz C, Wanono S, Morel J, Avouac J, Rozenberg F, Miceli-Richard C, and Fogel O

Subjects
Humans, SARS-CoV-2, Seroepidemiologic Studies, Serologic Tests, COVID-19 epidemiology, Rheumatic Diseases diagnosis, Rheumatic Diseases drug therapy, Rheumatic Diseases epidemiology
Abstract

Objectives: To estimate the seroprevalence of SARS-CoV-2 infection in patients with rheumatic diseases and to specify the proportion of asymptomatic and symptomatic forms of COVID-19., Methods: We screened for SARS-CoV-2 infection among spondyloarthritis (SpA, n=143) or rheumatoid arthritis (RA, n=140) patients in our outpatient clinic at Cochin Hospital in Paris between June and August 2020. We performed a qualitative SARS-CoV-2 serological test which detects IgG directed against the N nucleocapsid protein (anti-N) and, for some patients, against the Spike protein (anti-S). Descriptive analyses were managed., Results: During June-August 2020, the SARS-CoV-2 seroprevalence rate in our population was 2.83% (8/283 patients) without significant difference between RA and SpA patients (2.14% and 3.5%, respectively). We report 11 out of 283 patients (3.8%) with a diagnosis of SARS-CoV-2 infection. Among these 11 patients, 1 patient was asymptomatic (9%) with a confirmed diagnosis of COVID-19 by anti-S serology. Of the 283 patients, 85% were under bDMARDs, mainly on rituximab (RTX) (n=44) and infliximab (IFX) (n=136)., Conclusions: The seroprevalence of SARS-CoV-2 in patients with rheumatic diseases, mainly under bDMARDs treatments, was 2.83%. Among infected patients, 9% were asymptomatic. Detecting SARS-CoV-2 infections could be based on the strategy using patients' interview and anti-N serology., (Copyright © 2021 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.)

Published
2022
Full Text
View/download PDF

49. Screening of dental and sinus infections in rheumatoid arthritis.

Author

Descamps E, Gorlier C, Ottaviani S, Palazzo E, Dieudé P, and Forien M

Subjects
Adult, Aged, Arthritis, Rheumatoid epidemiology, Dental Caries diagnosis, Dental Caries epidemiology, Dental Caries therapy, Female, Focal Infection, Dental diagnosis, Focal Infection, Dental epidemiology, Humans, Male, Mass Screening, Middle Aged, Pulpitis diagnosis, Pulpitis epidemiology, Pulpitis therapy, Radiography, Panoramic, Retrospective Studies, Severity of Illness Index, Sinusitis diagnosis, Sinusitis epidemiology, Sinusitis therapy, Smoking epidemiology, Tomography, X-Ray Computed, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Biological Products therapeutic use, Dental Caries diagnostic imaging, Focal Infection, Dental diagnostic imaging, Pulpitis diagnostic imaging, Sinusitis diagnostic imaging
Abstract

Background: Rheumatoid arthritis (RA) is associated with increased risk of infections. Screening for oral (dental and/or sinus) infection could be proposed before biologic disease-modifying antirheumatic drugs (bDMARDs) initiation but is not systematically recommended. The aim of our study was to assess the prevalence of oral infection in RA patients requiring bDMARDs., Materials and Methods: This was a monocentric retrospective study. We included patients with RA and active disease requiring bDMARDs. Dental infection and sinusitis were assessed by a stomatologist and otorhinolaryngologist after clinical, panoramic dental X-ray and sinus CT evaluation. Factors associated with oral infections were analysed in uni- and multivariate models, estimating odds ratios (ORs) and 95% confidence intervals (CIs)., Results: We included 223 RA patients (79.4% women, mean disease duration 8.9 ± 8.6 years). The mean age was 54.4 ± 10.9 years and mean Disease Activity Score in 28 joints 5.5 ± 2.6. Systematic dental screening revealed infection requiring treatment before bDMARDs initiation in 46 (20.9%) patients. Sinusitis was diagnosed by the otorhinolaryngologist in 33 (14.8%) patients. Among the 223 patients, 69 (30.9%) had dental and/or sinus infection. On univariate analysis, active smoking was associated with increased probability of oral infection (OR = 2.16 [95% CI 1.02-4.57], P = .038) and methotrexate with reduced probability (OR = 0.43 [95% CI 0.23-0.81], P = .006). On multivariate analysis, no RA variables were associated with oral infection., Conclusion: In our study, asymptomatic oral infection was confirmed in one third of RA patients., (© 2020 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.)

Published
2021
Full Text
View/download PDF

50. Changes in bone formation regulator biomarkers in early axial spondyloarthritis.

Author

Descamps E, Molto A, Borderie D, Lories R, Richard CM, Pons M, Roux C, and Briot K

Subjects
Adult, Biomarkers blood, Cohort Studies, Disease Progression, Female, Follow-Up Studies, Humans, Male, Radiography, Spondylarthritis drug therapy, Tumor Necrosis Factor Inhibitors therapeutic use, Adaptor Proteins, Signal Transducing blood, Bone Morphogenetic Protein 7 blood, Intercellular Signaling Peptides and Proteins blood, Spondylarthritis blood
Abstract

Objective: The hallmark of advanced axial SpA (axSpA) is spine ankylosis due to excessive ectopic bone formation. This prospective study aimed to describe the changes in serum levels of different regulators [sclerostin, dickkopf-1 (DKK-1)] and markers of bone formation [bone morphogenetic protein 7 (BMP-7)] over 5 years in early axSpA patients and to assess determinants of such changes., Methods: The DEvenir des Spondyloarthropathies Indifférenciées Récentes cohort is a prospective, multicentre French study of 708 patients with early (>3 months-<3 years) inflammatory back pain suggestive of axSpA. Serum levels of BMP-7, sclerostin and DKK-1 were assessed at baseline and after 2 and 5 years. Changes in bone formation regulators over time were analysed using mixed linear models., Results: Serum BMP-7 significantly increased over time, with a median relative change of 223.7% [interquartile range (IQR) 0-10 700 (0.17 pg/ml/month), P < 0.001]. Serum sclerostin significantly increased over time, with a median relative change of 14.8% [IQR -7.9-41.4% (0.001 ng/ml/month), P < 0.001]. Serum DKK-1 did not significantly change over time. Serum BMP-7 increased over time in active disease (Ankylosing Spondylitis Disease Activity Score with CRP ≥1.3, P = 0.01), but the increase was less pronounced with TNF inhibitor (TNFi) use (P < 0.001). No determinant was associated with serum sclerostin change., Conclusion: Serum BMP-7 change over 5 years was related with inflammation; it was increased in active disease, but the increase was low with TNFi use. Serum sclerostin levels significantly increased over time, but to a lesser degree than for serum BMP-7., Clinical Trial Registration: https://clinicaltrials.gov/, NCT01648907., (© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results